ZIDOVUDINE by Cipla is [see microbiology ( )]. Approved for combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2008.
Drug data last refreshed 4h ago
[see Microbiology ( )].
Worked on ZIDOVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
A Study of Zidovudine in HIV-Infected Patients With Liver Disease
A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia